News

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Ron Lanton, partner, Lanton Law, explains that declining public trust and political support for vaccines could force pharmaceutical companies to rethink regulatory strategies and investment priorities ...